Xcout IntelEstrella Immunopharma, Inc. competitors & alternatives
The 11 closest competitors and alternatives to Estrella Immunopharma, Inc. among biopharmaceuticals companies — ranked by similarity to what Estrella Immunopharma, Inc. actually does, not by market-cap band.
Subscribe to see Estrella Immunopharma, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
Estrella Immunopharma, Inc. at a glance
Estrella Immunopharma, Inc. is a biopharmaceuticals company headquartered in EmeryVille, United States. It is publicly listed (ESLA) with a market capitalisation of $17.8M. Xcout tracks 14 named people at Estrella Immunopharma, Inc., including Cheng Liu (Chief Executive Officer, President & Director).
Estrella Immunopharma, Inc. leadership
- Cheng LiuChief Executive Officer, President & Director
- Jiandong XuChief Financial Officer
- Cheng LiuDirector
- Dengyao JiaDirector
- Fan WuDirector
- Hong ZhangDirector
8 more named people on record for Estrella Immunopharma, Inc., with roles, board committees and tenure — see the full roster →
Top 11 Estrella Immunopharma, Inc. competitors
Ranked by semantic similarity — how close each company is to Estrella Immunopharma, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Drug Discovery
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company headquartered in South San Francisco, California. It specializes in developing novel T-cell engaging therapies for the treatment of cancer.
Drug Discovery
BobcatBio, Inc. is a clinical-stage biotechnology company founded in 2020 and headquartered in Hummelstown, Pennsylvania. The company focuses on developing macrophage-based cell therapies and cancer-specific immunotherapies, including its lead cellular therapy candidate RB-1355, for the treatment of solid tumors.
Similar biopharmaceuticals company
Mabpharm Limited is a Chinese biopharmaceutical firm dedicated to the research, development, and manufacturing of innovative and biosimilar medications. Its therapeutic focus areas include allergic conditions, various cancers, and autoimmune disorders. The company boasts a robust pipeline, with several key products currently in advanced Phase III clinical trials. These include CMAB007, a recombinant humanized anti-IgE monoclonal antibody targeting asthma; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the initial treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody designed for moderate to severe active rheumatoid arthritis; and CMAB807, an agent developed for osteoporosis. Furthermore, Mabpharm is progressing various candidates through Phase I clinical development. Among these are CMAB819, aimed at treating metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X, formulated for tumor bone metastasis; and CMAB809, which targets HER2 overexpressing breast cancer and metastatic gastric cancer. The preclinical pipeline is equally extensive, featuring CMAB810 for breast cancer; CMAB816, addressing periodic fever syndrome, lung cancer, and systemic juvenile idiopathic arthritis; and CMAB017, intended for KRAS wild-type colorectal cancer. Also in preclinical stages are biosimilar candidates such as CMAB015, an analog of secukinumab for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a mepolizumab biosimilar for asthma and eosinophilic granulomatous polyangiitis; and CMAB022, designed for various inflammatory conditions. Beyond its product development, Mabpharm provides a range of related services, including contract research and development, technical consultation, technology transfer, and specialized technical support for biological products, diagnostic and chemical biological reagents, and pharmaceutical compounds. Established in 2018, Mabpharm Limited is headquartered in Taizhou, People's Republic of China.
Similar biopharmaceuticals company
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company located in South San Francisco and Mountain View, California. The company focuses on oncology, leveraging its proprietary Pro-XTEN technology platform to engineer novel protein therapeutics.
Similar biopharmaceuticals company
ChemoCentryx, Inc. is a biopharmaceutical company with its corporate headquarters and principal place of business located in California.
Similar biopharmaceuticals company
Artielle Immunotherapeutics is a venture-backed, clinical-stage biotechnology company pioneering novel therapeutics. It maintains its headquarters in Portland, Oregon, with additional presence in San Mateo, California.
Similar biopharmaceuticals company
ARMO BioSciences is a late-stage immuno-oncology company that develops a pipeline of novel, proprietary product candidates designed to activate the immune system of cancer patients to recognize and eradicate tumors.
Biotherapeutics
Headquartered in South San Francisco, California, Chimera Bioengineering is a privately held biotechnology company focused on developing advanced cellular engineering technologies for cancer therapies.
Biologics
Zumutor Biologics is an immuno-oncology company incorporated in the USA, with its primary office in Cambridge, Massachusetts. The company is a leading firm in the space of targeted NK cell therapeutics and utilizes proprietary naïve human phage/yeast display technology.
Biomedical
Lipomedix Pharmaceuticals Ltd. is a clinical-stage, oncology-focused pharmaceutical company developing cancer therapies based on liposome delivery technology. The company advances its drug pipeline through clinical trials, including Phase 1b and Phase 2A studies evaluated in medical centers in Israel.
Oncology
Neogene Therapeutics, Inc. is a global clinical-stage biotechnology company focused on the discovery and development of engineered T cell receptor therapies targeting cancer. The company has maintained dual headquarters with a U.S. base in Santa Monica, California, and an EU base in Amsterdam, before being acquired by AstraZeneca.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Estrella Immunopharma, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Estrella Immunopharma, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →